PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.00
Bid: 3.30
Ask: 4.50
Change: 0.00 (0.00%)
Spread: 1.20 (36.364%)
Open: 4.00
High: 0.00
Low: 0.00
Prev. Close: 4.00
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proteome Appoints Geoffrey Ellis As Finance Director, Loss Widens

Tue, 30th Sep 2014 09:41

LONDON (Alliance News) - Proteome Sciences PLC said Tuesday that has appointed Geoffrey Ellis as Finance Director, and posted a slightly widened pretax loss for the half-year to the end of June.

Ellis previously acted as chief financial officer of The Walt Disney Co's Network of Disney Channels in Europe, the Middle East and Africa, and managing director Disney Channel Scandinavia, Middle East and Emerging Markets.

Ellis succeeds James Malthouse, who is retiring after 20 years with the company.

Proteome posted a pretax loss of GBP2.1 million, widened from a loss of GBP1.9 million a year before, as revenue declined to GBP784,276 from GBP885,475, and administrative expenses rose slightly to GBP2.5 million from GBP2.3 million.

The company said following the growth in licensing, services and sales of its Tandem Mass Tag reagents in 2013, its core technologies had continued to strengthen in the first-half of 2014. Some contracts it was expecting were delayed, however, and the company said because of their size it is difficult to predict when they will come through.

Proteome said that whilst it is "difficult to be precise" over the timing of these revenue contributions, the scale and number of contracts in its order book is "growing steady and that performance is expected to continue in 2015."

Sales of Tandem Mass Tag reagent's rose 98% compared to the previous year. Proteome expects to see a more significant contribution from the products in the second-half, as well as continued improvement in its revenues from licences, sales and services.

Last Friday the company announced "excellent" results from in vitro toxicity tests for its two lead compounds to treat Alzheimer's disease, which it hopes will attract pharmaceutical companies to partner with Proteome on the treatments.

Shares in Proteome are trading down 8.0% at 35.18 pence Tuesday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
29 Jul 2021 18:17

TRADING UPDATES: Headlam boosts outlook; Mothercare loss widens

TRADING UPDATES: Headlam boosts outlook; Mothercare loss widens

Read more
18 Jun 2021 19:20

IN BRIEF: Proteome Sciences amends loan facility with Vulpes

IN BRIEF: Proteome Sciences amends loan facility with Vulpes

Read more
19 May 2021 19:33

TRADING UPDATES: Young's mulls asset sale; Ceres gets China investment

TRADING UPDATES: Young's mulls asset sale; Ceres gets China investment

Read more
5 May 2021 19:20

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

Read more
19 Apr 2021 20:40

IN BRIEF: Proteome Sciences Non-Executive Roger McDowell raises stake

IN BRIEF: Proteome Sciences Non-Executive Roger McDowell raises stake

Read more
1 Apr 2021 12:00

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

Read more
1 Apr 2021 10:34

AIM WINNERS & LOSERS: Oilex hails milestone with Cambay resolution

AIM WINNERS & LOSERS: Oilex hails milestone with Cambay resolution

Read more
31 Mar 2021 06:58

IN BRIEF: Proteome Sciences amends loan, gets extra year to pay back

IN BRIEF: Proteome Sciences amends loan, gets extra year to pay back

Read more
26 Mar 2021 13:02

Proteome profit to be higher than expected thanks to royalties boost

Proteome profit to be higher than expected thanks to royalties boost

Read more
26 Mar 2021 11:33

AIM WINNERS & LOSERS: Rotala skids on Burnham's Manchester bus reform

AIM WINNERS & LOSERS: Rotala skids on Burnham's Manchester bus reform

Read more
26 Mar 2021 08:37

Proteome expects FY profits to be 'materially higher' than previous guidance

(Sharecast News) - Protein biomarker research and development firm Proteome Sciences said on Friday that it has been progressing with a year-end audit and now expects to announce its 2020 full-year results on 1 April.

Read more
25 Jan 2021 16:17

TRADING UPDATES: IG Design Gets CSS Boost; FireAngel In Virus Hit

TRADING UPDATES: IG Design Gets CSS Boost; FireAngel In Virus Hit

Read more
14 Sep 2020 10:35

Proteome Shares Rise On Appointment Of Pharma Veteran Sohngen As CEO

Proteome Shares Rise On Appointment Of Pharma Veteran Sohngen As CEO

Read more
14 Sep 2020 08:39

Proteome Sciences announces new chief executive officer

(Sharecast News) - Proteome Sciences announced on Monday that Dr Mariola Söhngen has been appointed as a director and its chief executive officer, taking up the position on 15 September.

Read more
10 Aug 2020 10:15

Proteome First-Half Loss Widens As Cost Rise Trumps Revenue Climb

Proteome First-Half Loss Widens As Cost Rise Trumps Revenue Climb

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.